GlassScriptPhysician profile
Jeffrey A Heitmann
NPI 1407884034
$1,810.29
in general payments reported to CMS, 2019-2025
27 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $172 · 2021: $440 · 2022: $382 · 2023: $220 · 2024: $146 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.10 | 2020-2022 | |
| Exeltis, USA INC. | $241.22 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $202.10 | 2019-2025 | Aptima, Novasure |
| Pfizer INC. | $155.03 | 2019-2024 | |
| Therapeuticsmd, INC. | $143.94 | 2019-2022 | |
| Organon LLC | $103.75 | 2022-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $97.93 | 2019-2023 | Gardasil 9 |
| Millicent US INC | $65.65 | 2020-2024 | Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $64.60 | 2021-2024 | |
| Evofem Biosciences, INC. | $63.40 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $54.41 | 2019 | |
| Momentis Surgical INC. | $50.00 | 2022 | |
| Mayne Pharma Commercial LLC | $45.17 | 2021-2022 | |
| Avion Pharmaceuticals | $41.52 | 2022-2023 | Balcoltra |
| Amgen INC. | $28.35 | 2019-2025 | Evenity, Prolia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $23.96 | 2022 | |
| Duchesnay USA Incorporated | $20.51 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $19.70 | 2023 | Vivjoa |
| Axonics, INC. | $17.11 | 2022 | |
| Coopersurgical, INC. | $17.03 | 2021 | |
| Laborie Medical Technologies Corp. | $16.82 | 2023 | |
| Myovant Sciences INC. | $16.36 | 2022 | |
| Allergan, INC. | $16.32 | 2019 | |
| Astellas Pharma US INC | $16.01 | 2025 | Veozah |
| Lupin INC. | $13.31 | 2019 | |
| Agile Therapeutics, INC. | $11.99 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Heitmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.